Rhythm Pharmaceuticals and RareStone Ltd. Announce Exclusive Licensing Agreement for the Development and Commercialization of IMCIVREE (setmelanotide) in China

3 years ago

-- RareStone to seek marketing authorization for IMCIVREE to treat obesity due to biallelic POMC, PCSK1 and LEPR deficiencies and…

OPKO Health Announces the Passing of Director Dr. Richard Lerner

3 years ago

MIAMI, Dec. 06, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces that Director Richard A. Lerner, M.D. passed…

Vincerx Pharma Hosting Key Opinion Leader Webinar on VIP152 Data Presented at the American Society of Hematology Annual Meeting

3 years ago

PALO ALTO, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the…

iCAD Announces CEO Transition

3 years ago

Stacey Stevens Appointed as President and CEO and will Join the Board of Directors in 2022, Michael Klein to remain…

TFF Pharmaceuticals Hosting Science Day on December 13, 2021

3 years ago

AUSTIN, Texas, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing…

NGM Bio Announces Clinical Trial Collaboration with Merck Related to Ongoing Phase 1/2 Trial of NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Combination with Merck’s KEYTRUDA® (pembrolizumab)

3 years ago

NGM entered into a clinical trial collaboration and supply agreement with Merck to evaluate the potential of NGM707 in combination…

Chembio Diagnostics Submits FDA De Novo/510(k) Request for DPP SARS-CoV-2 Antigen Test System

3 years ago

HAUPPAUGE, N.Y., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious…

Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS)

3 years ago

HLHS is a rare congenital heart defect that affects approximately 1,000 babies in the U.S. per yearOrphan Drug Designation confers…

Ventyx Biosciences Announces First Patient Dosed in a Phase 2 Clinical Trial of VTX002 for the Treatment of Moderate-to-Severe Ulcerative Colitis

3 years ago

VTX002 is an oral, peripherally-restricted, selective sphingosine 1 phosphate receptor 1 (S1P1) receptor modulator internally discovered and developed by the…

Piezo Motion to Offer Precision Motor Technology and Automation across Asia

3 years ago

Piezo Motion’s new partnership with CNBEST Tech will expand access to affordable piezoelectric motor solutions in the Asian marketsNEW YORK,…